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TP63, a member of the TP53 gene family, encodes p63 
with 2 types of isoforms: a form with the N-terminal 
transactivation (TA) domain (TAp63) and a truncated 
form without the N-terminus (∆Np63). Both TAp63 and 
ΔNp63 have isoforms α, β, γ, δ, and ε owing to 
alternative splicing at the 3' end [1-5]. p63 shares 
structural and sequence homology with p53 and p73, 
the third member of the p53 family [1, 6]. Like p53, 
TAp63 has been implicated in cell cycle arrest and 
apoptosis in response to DNA damage, ectoderm 
development, maternal reproduction and metabolism, 
dependent or independent of p53-functions [1, 7-13]. 
For example, TAp63 can transactivate some well-
known p53 target genes including CDKN1A, BAX and 
MDM2 [1, 14]. Moreover, p53-dependent apoptosis in 
response to DNA damage required p63 and p73 in 
mouse developing brain and embryonic fibroblasts [7]. 
However, in a mouse model p63 and p73 did not 
contribute to p53 tumor suppression function in 
lymphoma development [15]. ∆Np63, on the other 
hand, interacts with p53, TAp63, and TAp73 in a 
dominant-negative fashion to inhibit their tumor-
suppressive functions [3]. It is generally believed that 
TAp63, like p53, is a tumor suppressor, whereas ∆Np63 
has a critical role in epidermal development and 
functions as an oncogene in a mouse model [16-19]. 
Furthermore, the α, β, γ, δ, and ε isoforms of TAp63 
and ΔNp63 have differential functions [5, 14, 20-24].  
 
In normal human tissues, p63 expression is tissue-
specific and restricted to epithelial cells, certain 
subpopulations of basal cells, and occasionally cells in 
the germinal centers of lymph nodes [1, 25, 26]. 
Accordingly, in tumors structural disruption of TP63 and 
aberrant p63 expression are commonly seen in squamous 
cell  and transitional cell carcinomas, but are also 
observed in non-Hodgkin lymphomas, predominantly in 
diffuse large B-cell lymphoma (DLBCL) and follicular 














In basal epithelial cells and squamous cell carcinomas, 
the ∆Np63 isoform, especially ∆Np63α, is 
predominantly expressed, possibly due to the increased 
∆Np63 stability caused by the lack of the transactivation 
domain which is indispensable for proteasome-
dependent MDM2-independent degradation of p63 [24, 
31]. In contrast, TAp63 is present mostly in epithelial 
lining cells at lower levels under normal physiological 
conditions, and in adenocarcinoma, thymoma and 
lymphoma cells; TAp63 accumulates in response to 
genotoxic stress [24, 26]. Although p63 expression has 
been shown in a few studies to indicate a poor prognosis 
in some carcinomas [32-34], its prognostic significance 
in DLBCL is unclear. 
 
DLBCL is the most common type of non-Hodgkin 
lymphoma and can be divided into germinal center B-
cell–like (GCB) and activated B-cell–like (ABC) 
subgroups by gene expression profiling [35]. Numerous 
genetic factors affecting the prognosis of DLBCL have 
been identified [36]. In our previous study, TP53 
mutations were detected in approximately 20% of de 
novo DLBCL cases and conferred a worse prognosis 
among DLBCL patients treated with rituximab, 
cyclophosphamide, doxorubicin, vincristine, and 
prednisolone (R-CHOP) [37]. Overexpression of 
mutated but not wild-type p53 (WT-p53) protein is also 
associated with a poor prognosis in DLBCL patients 
[38]. The dysregulation, expression, and clinical 
implications of p63 in DLBCL are less clear than those 
of p53; likewise, p63’s role in tumorigenesis and its 
functional relationship with p53 are not well 
understood. p63, predominantly TAp63 (likely TAp63β 
and/or TAp63γ) but not ∆Np63 or p63α, was found 
expressed in 15.1% to 52.5% of DLBCLs at higher 
levels than in normal lymphoid tissues [21, 25-27, 39]. 
Truncated p63 homologous to ∆Np63 due to TP63 gene 
rearrangements was also reported in 1.2%-5% of 
DLBCL, exclusive of GCB subtype [40, 41]. 
Abstract: The role of p53  family member, p63  in oncogenesis  is the subject of controversy. Limited research has been
done on the clinical implications of p63 expression in diffuse large B‐cell lymphoma (DLBCL). In this study, we assessed p63
expression  in  de  novo  DLBCL  samples  (n=795)  by  immunohistochemistry  with  a  pan‐p63‐monoclonal antibody  and
correlated  it with other clinicopathologic factors and clinical outcomes. p63 expression was observed  in 42.5% of DLBCL,
did not correlate with p53 levels, but correlated with p21, MDM2, p16INK4A, Ki‐67, Bcl‐6, IRF4/MUM‐1 and CD30 expression,
REL  gains,  and  BCL6  translocation.  p63  was  an  independent  favorable  prognostic  factor  in  DLBCL,  which  was  most
significant  in patients with International Prognostic  Index (IPI) >2, and  in activated‐B‐cell–like DLBCL patients with wide‐
type  TP53.  The  prognostic  impact  in  germinal‐center‐B‐cell–like DLBCL was  not  apparent, which was  likely due  to  the
association of p63 expression with high‐risk IPI, and potential presence of ∆Np63  isoform  in TP63 rearranged patients (a
mere  speculation). Gene expression profiling  suggested  that p63 has both overlapping and distinct  functions compared
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Conflicting results showing the effect of p63 expression 
on patients’ prognosis have been reported [21, 27, 39, 42, 
43], likely owing to small number of patients (fewer than 
100) in each study, the use of different cutoffs for p63 
positivity, the differential functions and complicated 
interactions of multiple p63 isoforms [23, 43].  
 
To fill this knowledge gap, we studied the prognostic 
effects of p63 expression correlating with TP53 status in 
a multicenter cohort of patients with well-characterized 
de novo DLBCL treated with R-CHOP. We found that 
p63 expression conferred better clinical outcomes in 
DLBCL which however could be compromised or 
abolished by the difference in International Prognostic 
Index (IPI) scores and/or the presence of TP53 mutations. 
We further investigated p63-associated biology to 






































p63 expression in DLBCL  
 
We observed nuclear expression of p63 at variable 
levels in tumor cells of 317 (61%) of 520 samples from 
patients in the training set and 180 (65%) of 275 
samples from patients in the validation set. 
Representative immunohistochemical stains are shown 
in Fig 1A, B and the histograms of p63 expression by 
immunohistochemistry are shown in Fig 1C, D. The 
mean number of p63 positive tumor cells in the training 
set was 18%, which was significantly higher than that of 
WT-p53 (P=0.017) but significantly lower than that of 
mutated p53 (MUT-p53, P<0.0001, Fig 1E) 
(Supplemental Fig 1A, B) [37, 38], although the TP63 






































Figure  1.  p63  expression  in  diffuse  large  B‐cell  lymphoma  (DLBCL)  in  comparison  with  p53  expression.  (A‐B) 
Representative  immunohistochemistry staining for p63 (10% and 95%)  in DLBCL. (C‐D) Histograms of p63 expression  in the training 
and  validation  sets.  (E) Comparisons between p63  and p53 expression  levels  in DLBCL.  (F) Comparisons between  TP63  and  TP53
mRNA levels in DLBCL. (G) p63+ DLBCL had significantly higher levels of TP63 mRNA compared with p63− DLBCL. (H) p63+ DLBCL had 
significantly higher TP53 mRNA  levels compared with p63− DLBCL.  (I) Expression of p63 protein correlated with TP63 mRNA  levels. 
The TP63 mRNA expression levels (Log2 values) were retrieved from the gene expression profiling data. The mean values of 3 probe‐
sets (1555581_a_at, 207382_at, 209863_s_at) for each patient were used. The relative mRNA level refers to the difference between 
the TP63 mRNA  level  for each patient and the mean TP63 mRNA  level for the entire cohort.  (J‐K) Comparisons of p63 protein and 
TP63 mRNA expression levels between germinal center B‐cell–like (GCB) and activated B‐cell–like (ABC) subtypes of DLBCL patients.  
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mRNA levels (P<0.0001, Fig 1F). p63 protein 
expression significantly correlated with TP63 mRNA 
(Spearman rank correlation: r=0.596, P<0.0001). 
 
Owing to the significantly lower level of p63 compared 
with MUT-p53 expression in DLBCL and the exclusion 
of potential false-positive cases, we used a cutoff value 
of 5% of tumor cells being p63-positive for p63 
expression in DLBCL (p63+: >5%). Using this cutoff, 
221 patients (42.5%) in the training set, and 130 (47%) 
of 275 patients in the validation set had p63+ DLBCL. 
The p63+ group showed a significantly higher mean 
TP63 mRNA level compared with the p63– group 
(unpaired t test, P<0.0001, Fig 1G) and TP53 mRNA 
level (Fig 1H). Transcriptional activation appeared to be 
the most common mechanism for p63 expression in this 
study of DLBCL (Fig 1I). No significant difference in 
the expression levels of p63/TP63 was observed 
between the GCB and ABC subtypes of tumor samples, 
either at the protein (16.66% vs. 19.26%, P=0.21) or 


































Clinical and pathobiological features of p63+ DLBCL  
 
We compared the clinicopathologic features of patients 
with p63+ and p63– DLBCL. The p63+ group more often 
had male (P=0.0056) and patients with small (< 5 cm) 
tumors (P=0.05) than did the p63– group. In addition, a 
higher proportion (41.9%) of p63+ patients had an IPI 
score >2 compared with p63– patients (34.4%), but this 
difference was not significant (P=0.086); however, by 
unpaired t test, patients with IPI scores >2 showed 
significantly higher mean levels of p63 (P=0.05, Fig 
2A) and MUT-p53 (P=0.011, figure not shown) than 
did patients with IPI scores ≤ 2. When DLBCL cases 
were stratified into the GCB and ABC subtypes, in 
GCB-DLBCL p63+ compared with p63– patients was 
associated with IPI scores >2, small tumors, and 
possibly stage III/IV disease (P=0.06), whereas in 
ABC-DLBCL p63+ patients had higher percentages of 
male gender and extranodal DLBCL (44% compared 
with the 31% in p63– ABC-DLBCL) (Table 1). In 
contrast, WT-p53 overexpression was more common in 


































Figure 2. Correlations between p63 expression and other  tumor associated  factors.  (A)  The  group with  high  International 
Prognostic  Index  (IPI)  scores  had  a  significantly  higher  mean  level  of  p63  expression.  (B‐D)  p63  expression  was  associated  with 
significantly higher levels of p21, MDM2, and p16‐INK4a in both germinal center B‐cell like (GCB) and activated B‐cell like (ABC) subtypes 
of DLBCL patients. (E‐F) p63 expression was associated with significantly higher  levels Ki‐67 and Bcl‐6  in ABC‐DLBCL. (G) p63 expression 










































































































DLBCL  GCB-DLBCL            ABC-DLBCL     
 
 p63+ p63-   p63+  p63-    p63+  p63-    
 N (%) N (%) P1   N (%)  N (%)  P2  N (%)  N (%)  P3 P4 
Patients 221 299   110  156    110  141  .59  
Age (yr)                 
< 60 92 (42) 133 (45) .52  52 (47)  84 (54)  .29  39 (35)  47 (33)  .73 .075 
≥ 60 129 (58) 166 (55)   58 (53)  72 (46)    71 (65)  94 (67)    
Sex                 
Female 76 (34) 139 (46) .0056  41 (37)  68 (44)  .30  34 (31)  70 (50)  .0028 .32 
Male 145 (66) 160 (54)   69 (63)  88 (56)    76 (69)  71 (50)    
Stage                 
I-II 94 (44) 141(49) .30  50 (48)  89 (59)  .06  44 (41)  51 (37)  .54 .34 
III-IV 119 (56) 148 (51)   55 (52)  61 (41)    63 (59)  86 (63)    
B symptoms                
No 136 (63) 183 (65) .63  73 (67)  101 (70)  .67  62 (58)  81 (60)  .76 .17 
Yes 79 (37) 97 (35)   35 (32)  43 (30)    44 (42)  53 (40)    
Serum LDH                 
Normal 79 (39) 107 (39) .97  42 (42)  56 (39)  .70  37 (36)  51 (39)  .71 .40 
Elevated 124 (61) 169 (61)   58 (58)  86 (61)    65 (64)  81 (61)    
No. of extranodal sites                
0-1 156 (75) 228 (79) .27  79 (78)  121 (81)  .56  76 (71)  106 (77)  .30 .23 
≥ 2 53 (25) 61 (21)   22 (22)  28 (19)    31 (29)  32 (23)    
Performance status                
0-1 164 (85) 225 (83) .66  78 (85)  119 (86)  .76  85 (84)  104 (79)  .35 .90 
≥ 2 30 (15) 46 (17)   14 (15)  19 (14)    16 (16)  27 (21)    
Size of largest tumor                
< 5cm 106 (65) 120 (55) .05  56 (70)  62 (55)  .04  49 (59)  58 (54)  .51 .14 
≥ 5cm 58 (35) 99 (45)   24 (30)  50 (45)    34 (41)  49 (46)    
IPI score                
0-2 125 (58) 189 (66) .086  65 (61)  111 (75)  .025  59 (55)  76 (56)  .90 .32 
3-5 90 (42) 99 (34)   41 (39)  38 (25)    49 (45)  61 (44)    
Therapy response                
CR 178 (81) 227 (76) .21  87 (79)  118 (76)  .51  90 (82)  104 (74)  .13 .61 
PR 24 43   13  19    11  24    
SD 8 13   6  7    2  6    
PD 11 16   4  12    7  7    
Primary origin                
Nodal 131 (60) 193 (66) .16  69 (64)  97 (64)  1.0  62 (56)  95 (69)  .048 .27 
Extranodal 88 (40) 99 (34)   39 (36)  55 (36)    48 (44)  43 (31)    
Ki-67                 
< 70% 66 (30) 119 (40) .0016  41 (37)  64 (42)  .45  24 (22)  55 (39)  .004 .018 
≥ 70% 155 (70) 175 (60)   69 (63)  88 (58)    86 (78)  86 (61)    
TP53 mutations                
WT-TP53 154 (80) 206 (77) .65  70 (74)  105 (76)  .76  83 (85)  100 (79)  .38 .059 
MUT-TP53 40 (21) 60 (23)   25 (26)  34 (24)    15 (15)  26 (21)    
MYC translocation               
No 138 (89) 158 (88) .86  62 (89)  73 (80)  .20  75 (89)  85 (95)  .15 1 
Yes 17 (11) 22 (12)   8 (11)  18 (20)    9 (11)  4 (5)    
BCL2 translocation                
No 159 (84) 187 (81) .44  68 (74)  74 (64)  .18  90 (94)  113 (97)  .31 .0002 
Yes 30 (16) 44 (19)   24 (26)  41 (36)    6 (6)  3 (3)    
BCL6 translocation                
No 98 (60) 145 (74) .0041  54 (69)  83 (78)  .16  43 (51)  61 (69)  .0016 .016 
Yes 66 (40) 51 (26)   24 (31)  23 (22)    42 (49)  28 (31)    
REL gains                
Normal 140 (86) 216 (92) .068  62 (77)  118 (92)  .003  77 (94)  98 (92)  .036 .0001 
Amplification/ polysomy 23 (14) 19 (8)   18 (23)  10 (8)    5 (6)  9 (8)    
REL amplification                
No 156 (95) 227 (97) .60  72 (91)  121 (95)  .40  83 (99)  106 (99)  1.0 .03 
Yes 8 (5) 8 (3)   7 (9)  7 (5)    1 (1)  1 (1)    
CD30 expression                
– 175 (79) 259 (88) .0048  86 (78)  133 (88)  .06  88 (80)  125 (89)  .049 .87 
+ 46 (21) 34 (12)   24 (22)  19 (12)    22 (20)  15 (11)    
p53 expression                
< 20% 116 (61) 172 (66) .27  57 (61)  89 (66)  .40  59 (62)  83 (66)  .48 1.0 
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When correlating p63 expression with other genetic 
abnormalities and immunohistochemical biomarkers in 
DLBCL, we found that the p63+ group had higher 
frequencies of BCL6 translocation and CD30 positivity 
(21% compared with the 12% in p63– patients) (Table 1), 
as well as elevated expression levels of Bcl-6, 
IRF4/MUM-1, p21, MDM2, p16-INK4a, and Ki-67 (in 
ABC-DLBCL only); most of  these associations were 
independent of TP53 mutation status (Fig 2B-L). In 
addition, p63 expression was associated with REL gains 
(including amplification and polysomies) in both the 
GCB and ABC subsets. No significant differences in 
frequencies of TP53 mutations, MYC or BCL2 
translocations, or the expression levels of p53, Myc, or 







































p63 expression confers better clinical outcomes, 
more apparently in high-risk DLBCL and ABC-
DLBCL 
 
Univariate survival analysis in the training set 
With a median follow-up of 62 months, p63+ DLBCL 
patients showed better progression-free survival (PFS, 
P=0.05) compared with p63– DLBCL patients (Fig 3a, 
b). When patients with low-risk (IPI score ≤ 2) and 
high-risk DLBCL (IPI score >2) were analyzed 
separately (Fig 3c, d), p63 expression showed 
prognostic significance only in the high-risk group and 
correlated with significantly better overall survival (OS) 



























































































When analyzed in GCB- and ABC-DLBCL subsets 
separately, patients with p63+ ABC-DLBCL showed 
significantly better PFS (P=0.0097) and a trend of better 
OS (P=0.08) compared with p63– ABC-DLBCL 
patients. In contrast, in GCB-DLBCL, p63 expression 
did not show significant impact on OS or PFS (Fig 3e-
h). Consistently, survival analysis based on TP63 
mRNA levels showed that TP63 mRNA expression 
correlated with favorable OS and significantly better 
PFS in ABC-DLBCL patients only (P=0.06 and 













































Since the p63+ GCB-DLBCL group had a higher 
portion of patients with high-risk DLBCL (Table 1) 
which may have confounded the analysis [44], patients 
with low-risk and high-risk DLBCL were analyzed 
separately. In GCB-DLBCL patients with IPI scores >2, 
p63+ GCB-DLBCL patients showed trends of better OS 
and PFS (P=0.078 and P=0.057 respectively) (Fig 3i-j). 
Similarly, the prognostic impact of p63 expression in 
ABC-DLBCL patients was more apparent in those with 
IPI scores >2 (Fig 3k-l); For ABC-DLBCL patients with 
IPI scores ≤ 2, OS and PFS rates were higher for  p63+ 
Table 2. Multivariate survival analysis 
  OS    PFS  
Variable HR 95% CI P  HR 95% CI P 
Overall DLBCL        
 IPI >2 3.08 2.21-4.38 < .0001  2.84 2.08-3.89 < .0001 
p63+ .62 .45- .87 .006  .66 .48- .90 .009 
Female sex .86 .62-1.20 .37  .92 .67-1.26 .60 
Tumor size ≥5 cm 1.30 .94-1.79 .11  1.26 .93-1.70 .14 
B symptoms present 1.32 .95-1.85 .10  1.24 .90-1.71 .18 
GCB-DLBCL        
 IPI >2 4.00 2.36-6.79 < .0001  3.44 2.27-5.21 < .0001 
p63+ .64 .41- .99 .045  .67 .42-1.09 .11 
Female sex .94 .61-1.45 .78  1.00 .67-1.50 .99 
Tumor size ≥5 cm 1.53 .92-2.54 .10  1.46 .92-2.34 .11 
B symptoms present 1.08 .69-1.70 .74  1.21 .74-1.98 .44 
ABC-DLBCL        
 IPI >2 2.35 1.61-3.43 < .0001  2.23 1.57-3.16 < .0001 
p63+ .56 .38- .83 .004  .58 .40- .83 .003 
Female sex .77 .52-1.15 .20  .78 .54-1.12 .17 
Tumor size ≥5 cm 1.03 .58-1.56 .88  .99 .66-1.47 .94 
B symptoms present 1.06 .72-1.58 .76  1.14 .79-1.64 .49 
DLBCL with WT-TP53       
 IPI >2 3.29 2.21-4.88 < .0001  3.21 2.18-4.72 < .0001 
p63+ .61 .40- .91 .015  .63 .43- .92 .016 
p53+ .97 .62-1.52 .90  .91 .60-1.40 .68 
Female sex .91 .61-1.36 .65  .85 .57-1.26 .42 
Tumor size ≥5 cm 1.19 .81-176 .38  1.11 .76-1.62 .59 
B symptoms present 1.45 .97-2.17 .07  1.48 1.00-2.20 .049 
DLBCL with MUT-TP53       
 IPI >2 2.43 1.17-5.05 .017  2.11 1.07-4.18 .032 
p63+ .70 .34-1.44 .33  .72 .36-1.44 .36 
p53+ 3.16 1.17-8.52 .023  2.30 .97-5.45 .06 
Female sex 1.02 .50-2.11 .96  1.12 .57-2.20 .75 
Tumor size ≥5 cm 1.57 .77-3.20 .21  1.85 .95-3.63 .07 
B symptoms present 1.19 .54-2.60 .67  1.03 .49-2.17 .93 
Abbreviations:  DLBCL,  diffuse  large  B‐cell  lymphoma;  ABC,  activated  B‐cell–like;  OS,  overall  survival;  PFS,  progression‐free 
survival; HR, hazard ratio; CI, confidence interval; IPI, International Prognostic Index. 
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patients but not the differences were not significant 
(P=0.48 and P=0.12 respectively). 
 
Multivariate survival analysis 
We performed multivariate survival analysis for p63 
expression adjustin g clinic al parameters including IPI 
score, sex, tumor size and B symptoms. p63 
expression was found to be an independent prognostic 
factor for better OS in the overall DLBCL, GCB-
DLBCL and ABC-DLBCL sets, and an independent 
prognostic factor for better PFS in the overall DLBCL 
and ABC-DLBCL sets but not in the GCB-DLBCL set 












































Similar to the training set, no significant difference was 
observed in p63 expression between the GCB and ABC 
subtypes (P=0.68). These similar prognostic impacts as 
in the training set were all significant with a ≥5% cutoff 
value for p63 expression (P=0.02, P=0.047, and 
P=0.0007 for PFS in DLBCL, ABC-DLBCL and high-
risk DLBCL respectively. Supplemental Fig S2). A 
multivariate survival analysis indicated that after 
adjusting clinical parameters, p63 expresssion ≥5% was 
an independent favorable prognostic factor in overall 
DLBCL and ABC-DLBCL but not in GCB-DLBCL 
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Relationships with TP53 mutations and p53 
expression 
 
Non-significant correlation with p53 expression and 
correlation with TP53 mRNA 
By Spearman rank correlation TP63 mRNA showed 
correlation with TP53 mRNA levels in the overall 
DLBCL set (r=0.091, P=0.048) and WT-TP53 subset 
(r=0.106, P=0.044) but not in the MUT-TP53 subset. In 
contrast, p63 expression did not show significant 
correlation with overall p53 (r=0.071, P=0.132), WT-
p53 (r=0.08, P=0.135), or MUT-p53 (r=0.072, 
P=0.481). Using unpaired t-tests, p63 expression did not 
correlate with p53 levels (Supplemental Fig S1C), but 
was associated with elevated TP53 mRNA levels (Fig 








































p53 or MUT-p53 showed no significant correlations 
between p63 positivity and WT-p53/MUT-p53 
expression levels (Table 1, Fig 4A, B). However, the 
WT-p53+ (≥20% [38]) compared with the WT-p53– 
DLBCL group had a significantly higher mean level of 
p63 protein (Fig 4C(b)) but not TP63 mRNA (Fig 4D). 
 
Prognostic impact of p63 expression in the presence of 
WT-TP53 or MUT-TP53 
The clinicopathologic features of patients with p63+ or 
p63– DLBCL with WT-TP53 or MUT-TP53 are shown in 
Table 3. p63 expression was associated with significantly 
better OS and PFS in patients with WT-TP53 and IPI 
scores >2 (Fig 5A, B) and in ABC-DLBCL patients with 
WT-TP53 (Fig 5C, D), and favorable trends in patients 
































































































































































  WT-TP53                         MUT-TP53   
  p63+  p63–    p63+  p63–   
Characteristic  N (%)  N (%)  P   N (%)  N (%)  P  
Patients  154  206    40  60   
Age (y)            
< 60  62 (40)  87 (42)  .75  16 (40)  25 (42)  1.0
≥ 60  92 (60)  119 (58)    24 (60)  35 (58)   
Gender             
Male  106 (69)  107 (52)  .0013  24 (60)  36 (60)  1.0 
Female  48 (31)  99 (48)    16 (40)  24 (40)   
Stage             
I-II  62 (42)  97 (49)  .21  17 (43)  28 (47)  .68 
III-IV  84 (58)  100 (51)    23 (58)  32 (53)   
B symptoms            
No  100 (67)  196 (66)  .92  23 (59)  38 (68)  .37 
Yes  50 (33)  65 (34)    16 (41)  18 (32)   
LDH             
Normal  58 (41)  82 (44)  .66  12 (32)  19 (33)  .93 
Elevated  82 (59)  105 (56)    25 (68)  38 (67)   
No. of extranodal sites           
0-1  105 (73)  155 (78)  .30  29 (74)  46 (78)  .68 
≥ 2  38 (27)  43 (22)    10 (26)  13 (22)   
Performance status            
0-1  117 (87)  231 (85)  .62  30 (88)  50 (86)  .78 
≥ 2  18 (13)  28 (15)    4 (12)  8 (14)   
Size of largest tumor            
< 5cm  81 (68)  90 (58)  .079  18 (58)  23 (48)  .38 
≥ 5cm  38 (32)  66 (42)    13 (42)  25 (52)   
IPI risk group            
0-2  87 (58)  132 (67)  .10  19 (49)  38 (64)  .12 
3-5  62 (42)  65 (33)    20 (51)  21 (36)   
Therapy response            
CR  126 (82)  163 (79)  .59  27 (68)  35 (58)  .40 
PR  16  24    7  13   
SD  3  7    3  3   
PD  9  12    3  9   
Ki-67            
< 70% 50 (33)  83 (41)  .10  9 (22)  17 (29)  .64 
≥ 70% 104 (67)  119 (59)    31 (78)  42 (71)   
Primary origin            
Nodal  91 (40)  134 (66)  .21  25 (37)  39 (70)  .54 
Extranodal  61 (60)  68 (66)    15 (63)  17 (30)   
DLBCL subtypes             
GCB  70 (46)  105 (51)  .34  25 (62)  34 (57)  .68 
ABC  83 (54)  100 (49)    15 (38)  26 (43)   
BCL6 translocation            
–  73 (63)  97 (70)  .21  17(57)  35 (85)  .007 
+   43 (37)  41 (30)    13(43)  6 (15)   
CD30            
–  120 (78)  178 (89)  .0085  32 (80)  54 (92)  .13 
+   34 (22)  23 (11)    8 (20)  5 (8.5)   
p53 expression             
< 20%  106 (70)  154 (77)  .18  10 (26)  18 (31)  .65 
≥ 20%  45 (30)  47 (23)    29 (74)  40 (69)   
Abbreviations: DLBCL, diffuse  large B‐cell  lymphoma; R‐CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; 
LDH,  lactate  dehydrogenase;  IPI,  international  prognostic  index;  CR,  complete  remission;  PR,  partial  response;  SD,  stable  disease;  PD, 
progressive disease; GCB, germinal center B‐cell–like; ABC, activated B‐cell–like.  
  






































Multivariate survival analysis 
We further performed multivariate survival analysis 
including p63 expression, p53 overexpression, and 
clinical parameters in the WT-TP53 and MUT-TP53 
subsets individually. In the WT-TP53 subset, p63 
expression but not WT-p53  overexpression remained as 
an independent prognostic factor for better OS and PFS;  
in the MUT-TP53 subset, MUT-p53 overexpression but 
not p63 expression was an independent prognostic 
factor for poorer PFS (borderline P value for OS) 
(Table 2).  
 
Gene expression profiling signature of p63 
expression  
 
To gain insights into the potential molecular 
mechanisms underlying the prognostic observation, we 






































p63– patients in the overall DLBCL group and various 
subsets stratified by GCB/ABC subtype, TP53 mutation 
and p53 overexpression status (Fig 6A-H, Supplemental 
Fig S3A-D). Counts of significant differentially 
expressed genes (DEGs) between compared groups with 
different false discovery rate (FDR) thresholds are listed 
in Supplemental Table S1. Largely, whether p63 
expression was associated with distinct GEP signatures 
did not correlated with whether p63 showed apparent 
prognostic effects, and the GEP signature of p63 
expression in the MUT-TP53 subset was much more 
prominent (Fig 6B, Table 4) than that in the WT-TP53 
subset (7 genes only with a FDR threshold of 0.30, 
figure not shown). However, after dividing the WT-
TP53 subset into GCB and ABC subtypes of DLBCL 
patients, p63 expression showed GEP signatures, more 
distinctive in ABC than in GCB (Fig 6C, Supplemental 
Fig S3A), which was opposite to the pattern for overall 
Table 4. Genes differentially expressed between patients with p63+ and p63– DLBCL 
 p63+ DLBCL  
FDR< 0.20 
 p63+ DLBCL with MUT-TP53 
FDR< 0.05, fold change > 1.68 
p63+ ABC-DLBCL with WT-
TP53 FDR< 0.20 
Function 
categories 
Upregulated   Downregulated   Upregula
ted  
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ABC and GCB (only few DEGs in ABC compared to 
the distinct GEP signature in GCB, Supplemental Table 
S1). The p63 GEP signatures in the MUT-TP53 and 
WT-TP53 subsets had both similarity (upregulated 
ATP2A2 and downregulated ZNF652) and difference 
(three genes, GABBR2, PDHA1 and NFYB, showed 
opposite up- or down-regulation). Reinforcing the idea 
that p63 GEP signatures are more highlighted in the 
absence of WT-p53 activities as shown in the MUT-
TP53 subset, we further found that in WT-p53– ABC-
DLBCL but not in WT-p53+ ABC-DLBCL, p63 
expression was associated with significant DEGs 
(Supplemental Fig S3B, Supplemental Table S3). 
 
To gain insights into the functional relationship between 
p53 and p63, we further analyzed the overlap and 
difference between the p53 [37, 38] and p63 GEP 





































had a WT-p53-like GEP signature either in the context 
of WT-TP53 (such as CTAG2,  SOX4 and ELL2, 
accounting for approximately 21% of the DEGs 
between WT-TP53/p63+ and WT-TP53/p63–) or MUT-
TP53 (such as DSE, ATM, CDK13, CD47, ELF1, 
DYRK1A [45], PFDN4, and TMEM97, accounting for 
approximately 4% of the DEGs between MUT-
TP53/p63+ and MUT-TP53/p63–), yet remained some 
MUT-p53-like GEP signature mainly in the context of 
MUT-TP53 (such as CAMTA1 resembling the MUT-p53 
GEP signature, and ABHD11, KCNN3, MART3, and 
MRPL30 opposite to the WT-p53 GEP signature; 
accounting for approximately 1.4% of the DEGs 
between MUT-TP53/p63+ and MUT-TP53/p63–). 
Moreover, only in the p63+ but not in the p63− subset, 
expression of WT-p53 or MUT-p53 was associated with 
distinct GEP signatures (Fig 6G, H), which may suggest 






































Figure  6.  Gene  expression  profiling  analysis.  (A)  Heatmap  for  comparison  between  p63+  and  p63−  DLBCL  patients  (false
discovery rate < 0.15).  (B) Heatmap  for comparison between p63+ and p63− DLBCL patients with MUT‐TP53  (false discovery rate <
0.05,  fold  change  >1.68).  (C)  Heatmap  for  comparison  between  p63+  versus  p63−  patients with  ABC‐DLBCL  and  WT‐TP53  (false
discovery rate < 0.20). (D) Heatmap for comparison between p63+ versus p63− patients with GCB‐DLBCL (false discovery rate < 0.05). 
  









































We also compared the p63 GEP signature with the 
MDM2 GEP signature [38], and found 21 DEGs were 
common between the GEP signatures of p63 and 
MDM2 expression, among which 16 DEGs were not 
shared by the p53 GEP signature (Table 5).  
 
Although the p53 and p63 GEP signatures overlapped, 
majority of the DEGs were not shared. Nonetheless, a 
p53-like tumor suppressor role of p63 was suggested by 
the p63 GEP signatures, including downregulation of 
CCND2 (in WT-TP53/p63+ ABC-DLBCL), CDC27 and 
MYCT1  (in  WT-TP53/p63+  GCB-DLBCL),  CDC2L5/ 
CDK13 and CXCR4 (in MUT-TP53/p63+ DLBCL. TP53 
mutations were associated with increased CXCR4 levels 









































[46]), ELF1 which encodes a transcription factor that 
activates LYN and BLK (in MUT-TP53/p63+ GCB-
DLBCL), MYBL1 and STRBP which play roles in 
proliferation and growth (in MUT-TP53/p63+ GCB-
DLBCL), antiapoptotic C9orf82 and BCOR (which 
encodes an interacting corepressor of BCL6 required for 
germinal center formation and may influence apoptosis) 
(in MUT-TP53/p63+ ABC-DLBCL), as well as 
upregulation of HIPK2 (which promotes apoptosis 
through the activation of p53/TP53) (in p63+ DLBCL) 
and WWOX (which functions synergistically with 
p53/TP53 to control genotoxic stress-induced cell 
death) (in MUT-TP53/p63+ ABC-DLBCL) (Supplemen-
























































































































Common genes shared by the p63+ and p53+ signatures 
   WT-TP53 
  WT-p53+ vs WT-p53– 
MUT-TP53 
 MUT-p53+ vs WT-p53– 
MUT-TP53 vs WT-TP53 
  Same  Same 
Up ↑ DSE ↑ in MUT-TP53/p63+ vs MUT-TP53/p63–
↑ in MUT-p53+/p63+ vs MUT-p53+/p63– 
BCAS1 ↑ in p63+ GCB vs p63– GCB 
 ELL2 ↑ in WT-TP53/p63+ vs WT-TP53/p63–   
 FDXR ↑ in WT-p53−/p63+ ABC vs WT-p53–/p63– ABC   
 GRRP1 ↑ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 HPGD ↑ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 PFDN4 ↑ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 SOX4 ↑ in p63+ vs p63– 
↑ in WT-TP53/p63+ vs WT-TP53/p63– 






↓ in MUT-TP53/p63+ vs MUT-TP53/p63– CAMTA1 ↓ in MUT-TP53/p63+ vs MUT-
TP53/p63– 
↓ in MUT-TP53/p63+ GCB vs MUT-
TP53/p63– GCB 
 C3orf63 ↓ in MUT-p53+/p63+ vs MUT-p53+/p63–   
 CCDC69 ↓ in p63+ GCB vs p63– GCB   
 CD47 ↓ in MUT-p53+/p63+ vs MUT-p53+/p63–   
 CDC2L5/C
DK13 
↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-TP53/p63+ GCB vs MUT-TP53/p63– 
GCB 
  
 DCLRE1C ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-TP53/p63+ GCB vs MUT-TP53/p63– 
GCB 
  
 DYRK1A ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 ELF1 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-TP53/p63+ GCB vs MUT-TP53/p63– 
GCB 
↓ in p63+ GCB vs p63– GCB 
  
 ESR2 ↓ in p63+ GCB vs p63– GCB   
 HCG18 ↓ in WT-TP53/p63+ vs WT-TP53/p63–   
 HERC4 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-TP53/p63+ GCB vs MUT-TP53/p63– 
GCB 
  
 ITCH ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 LOC645513 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 ORC4L ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 PPP1R2 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 TBC1D1 ↓ in p63+ vs p63– 
↓ in p63+ GCB vs p63– GCB 
  
 PXK ↓ in p63+ GCB vs p63– GCB   
 TMCC1 ↓ in MUT-TP53/p63+ ABC vs MUT-TP53/p63– 
ABC 
  
 ZCCHC7 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 ZNF221 ↓ in WT-p53−/p63+ ABC vs WT-p53–/p63– ABC   
 Opposite  Opposite 
Up ↑ KCNN3 ↓ in p63+ GCB vs p63– GCB CTAG2  ↓ in WT-p53−/p63+ ABC vs WT-p53–
/p63– ABC 
 KIAA0564 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-p53+/p63+ vs MUT-p53+/p63– 
TMEM97 ↓ in MUT-TP53/p63+ vs MUT-
TP53/p63– 
 MATR3 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63– SLC16A1 ↓ in p63+ GCB vs p63– GCB 
 MRPL30 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
Down 
↓ 
















































On the other hand, some DEGs promoting tumor cell 
survival were also shown in the comparison between 
overall p63+ and p63– DLBCL patients, which may be 
due to the oncogenic function provided by MUT-p53 or 
p63 isoforms in the p63+ DLBCL subsets. For example, 
antiapoptotic BCL2L1, RFFL (which negatively 
regulates p53, CASP8 and CASP10 through 
proteasomal degradation), ATG4B (required for 
autophagy), and MKL1 (which suppresses TNF-induced 













































regulated in p63+ DLBCL compared with  p63– 
DLBCL, whereas C13orf15/RGCC (in response to 
DNA damage) was downregulated in p63+ DLBCL 
patients (Table 4). Cytokine/receptor genes IL17RC, 
IL4, IL4I1 and IL8RB/CXCR2 which have been 
associated with poorer prognosis in cancers, were 
upregulated in MUT-TP53/p63+ compared with MUT-
TP53/p63– DLBCL (Supplemental Table S2); MLL2 
was upregulated in p63+ patients with ABC-DLBCL 
and MUT-TP53 (Supplemental Fig S3D).  
 
 
Common genes shared by the p63+ and MDM2+ signatures 
 WT-TP53  MUT-TP53  
 MDM2+ vs MDM2– MDM2+ vs MDM2– 
  Same  Same 
Up ↑ FAM83A ↑ in MUT-TP53/p63+ ABC vs MUT-TP53/p63– 
ABC 
  
 FDXR ↑ in WT-p53−/p63+ ABC vs WT-p53–/p63– 
ABC 
  
 MICAL2 ↑ in MUT-TP53/p63+ GCB vs MUT-TP53/p63– 
GCB 
  
 PCBP3 ↑ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 TCEB3 ↑ in p63+ vs p63–   
Down ↓ ATM ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 BPTF ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in p63+ GCB vs p63– GCB 
ATG7 ↓ in p63+ GCB vs p63– GCB 
 BRWD1 ↓ in p63+ GCB vs p63– GCB ATP5C1 ↓ in MUT-TP53/p63+ vs MUT-
TP53/p63– 
↓ in MUT-TP53/p63+ GCB vs MUT-
TP53/p63– GCB 
 CD22 ↓ in p63+ GCB vs p63– GCB EIF2A ↓ in MUT-TP53/p63+ vs MUT-
TP53/p63– 
 DHX36 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–  PAK2 ↓ in MUT-TP53/p63+ vs MUT-
TP53/p63– 
 EIF2A ↓ in MUT-TP53/p63+ vs MUT-TP53/p63– PRICKLE4/
TOMM6 
↓ in MUT-TP53/p63+ ABC vs MUT-
TP53/p63– ABC 
 NKTR ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-p53+/p63+ vs MUT-p53+/p63– 
↓ in MUT-TP53/p63+ GCB vs MUT-TP53/p63– 
GCB 
  
 RBM26 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–
↓ in MUT-p53−/p63+ vs MUT-p53−/p63– 
  
 RPL34 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 SLC35F5 ↓ in MUT-TP53/p63+ vs MUT-TP53/p63–   
 
WT-TP53 MDM2+ vs MUT-TP53 MDM2+   
 Same   
Down ↓ LPP ↓ in p63+ GCB vs p63– GCB   
  



























Abnormal p63 expression patterns instead of TP63 
mutations have been found to be important for 
tumorigenesis [5]. Little data are available with 
conflicting results regarding p63 expression and its 
prognostic role [27, 39, 43]. We found that p63 
expression correlated with a superior survival in ABC-
DLBCL with WT-TP53 and in high-risk (IPI >2) 
DLBCL (regardless GCB or ABC), which is consistent 
with a previous study in high-intermediate and high risk 
DLBCL [27]. The association of p63 expression with 
high-risk IPI in GCB-DLBCL, and thus affecting its 
apparent prognostic effects in GCB and overall 
DLBCL, may contribute to the inconsistent findings 
from previous studies.  
 
The prognostic effect of p63 expression suggests that 
p63 has a tumor suppressor role for DLBCL, although 
its protective effect can be antagonized or abolished by 
TP53 mutations and high-risk DLBCL associated 
biology. In our cohort, p63 expression was associated 
with increased levels of IRF4/MUM-1, p21, MDM2, 
and p16-INK4a resembling that of WT-p53 yet 
independent of p53 mutation status. GEP analysis 
showed that compared to the prominent p63 GEP 





























between p63+ and p63– patients with WT-TP53 had 
much fewer DEGs; DEGs were shown within the WT-
p53– but not WT-p53+ ABC-DLBCL subset. These 
results may suggest that the tumor suppressor function 
of p63 may overlap with (and is probably weaker than) 
that of WT-p53, and when TP53 was mutated, p63 
functions as a supplemental tumor suppressor 
alternative to WT-p53. However, MUT-p53 function 
remained or dominated p63 function in certain MUT-
TP53 cases (Table 5), likely due to the significantly 
higher levels of MUT-p53 than p63 [47]. In addition to 
the GEP results as above, p63 expression correlated 
with MDM2 upregulation and BCL2 and MDM4 
downregulation (P=0.0174, P=0.0487 and P=0.090 
respectively) resembling WT-p53 expression GEP 
signature (although the FDRs for the comparison 
between p63+ and p63− DLBCL were higher). In 
contrast, CDKN1A/p21, MCL1, B2M, and FYB showed 
great variation even opposite up/down regulation 
between the WT-p53+ and the p63+ GEP signature. 
These phenomena may be explained by the remained 
MUT-p53-like function in the MUT-TP53/p63+ cases, 
whereas TP63 mutations and expression of different 
p63 isoforms may not be significant factors as 
suggested by the previous studies [5, 25, 43] and our 
preliminary data of TP63 mutations in DLBCL 
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These observations in DLBCL may support previous 
functional studies, which showed that TAp63α and 
TAp63γ (but not ΔNp63) could induce apoptosis at 
lesser levels than WT-p53 [48]; TAp63, and also 
TAp73, together with p53, may transactivate a group of 
common target genes in response to DNA damage, 
including damage resulting from exposure to 
doxorubicin, a component of R-CHOP; 1 TAp63 and 
MUT-p53 antagonize each other mainly in the 
regulation of metastasis and tumor dissemination [5]; 
p53 mutants may bind directly to p63 and inhibit the 
p63-mediated transcription of p53 target genes [49, 50]. 
Strategies to overcome MUT-p53 interaction with p63, 
decrease MUT-p53 levels and enhance p63 levels may 
have therapeutic value [47]. On the other hand, in 
mouse embryonic fibroblasts, p63 and p73 are required 
for p53-dependent apoptosis in response to DNA 
damage [7]. This may explain why our GEP 
comparisons between p53+ and p53– DLBCL showed 
DEGs within the p63+ but not p63– subset. Moreover, 
our data suggested that p63 act together with p53 in 
some essential pathways yet also function 
independently in many processes such as development, 
immune response and chemokinesis. Large variations 
between p63 signatures in the overall DLBCL patient 
population and in the GCB and ABC subsets may also 
imply a wide range of p63 activities. These 
characteristics of p63 function compared with p53, as 
well as association with high Ki-67 (consistent with 
previous studies [21, 43]) and high IPI may explain the 
limitation of p63’s apparent prognostic effect in DLBCL.   
 
It is also possible that the correlation between p63 
expression and better survival outcomes may be also 
influenced by the escape from MDM2-mediated 
degradation. In our cohort, the p63’s protective effects on 
patient survival were independent of MDM2 expression, 
yet GEP signatures were only shown in MDM2low but not 
in MDM2high subsets (data not shown), suggesting that 
MDM2 may suppress p63 function but the suppression is 
not significant to the p63’s protective effect. Conversely, 
p63 may have confounded the MDM2’s prognostic effect 
in DLBCL just as that of WT-p53 [38], suggested by the 
common genes shared by the MDM2 and p63 GEP 
signatures (Table 5). Previous studies have suggested that 
p63 degradation is independent of MDM2 [24, 31] and 
that MDM2 increases the protein level and transcriptional 
activity of p63 [51]. The MDM2 inhibitor p14ARF 
directly interacts with and impairs p63 transcriptional 
activity [52]. On the other hand, it has also been shown 
that MDM2 transports p63 out of nucleus and inhibits its 
transcription function [53].  
 
Yang et al. speculated that p63 expression in cancer 
cells was due to TP63 gene amplification by genomic 
instability [3], and other researches showed that p63 
expression was regulated via mRNA stability [4, 19]. 
TP63 rearrangements have been reported in 1.2-5% of 
DLBCL (exclusive of GCB subtype) and also in 5.8% 
of peripheral T-cell lymphomas, which resulted in a 
truncated p63 protein lacking the TA domain [40, 41]. 
Our data showed the associations of p63 expression 
with BCL6 (mapped to 3q27) translocations, which 
appears to suggest the possibility of concurrent 
translocation of TP63 gene (mapped to 3q27-28) due to 
chromosomal proximity in p63+ DLBCL subsets. In 
these cases it is possible that expressed p63 had 
oncogenic function like ∆Np63, which may explain the 
oncogenic DEGs in the p63 GEP signatures, and the 
lack of p63’s prognostic significance in GCB-DLBCL. 
In addition, genomic stress similar to that inducing p53 
may also be the cause of p63 expression in subsets of 
p63+ DLBCL [54], since our data showed correlation 
between the WT-TP53 and TP63 mRNA levels, and 
both WT-p53 and p63 expression were associated with 
increased IRF4/MUM-1 and Ki-67 expression. Fig 7 
illustrates these potential causes for p63 expression and 
possible relationships between p63 and WT-p53/MUT-
p53 function. Understanding the mechanisms regulating 
TP63 may lead to therapeutic strategies. In DLBCL cell 
lines, FOXP1, directly represses TP63 and cooperate 
with NF-κB signaling to promote lymphoma cell 
survival [42]. Consistently, our GEP data also suggest 
that molecules related to B-cell receptor signaling may 
be potential targets which suppresses p63 expression, as 
in GCB-DLBCL and MUT-TP53/p63+ DLBCL, p63 
expression was associated with downregulation of SYK 
and ELF1 respectively (suggesting decreased B-cell 
receptor signaling).  
 
In conclusion, we demonstrated the correlation of p63 
expression and better survival outcomes in patients with 
high-risk DLBCL, ABC-DLBCL with WT-TP53, and 
biology associated with p63 expression supporting 
p63’s tumor suppressor role in DLBCL. This study 
helps identify a subgroup of patients with better 
prognosis among patients who have ABC-DLBCL or 
high-risk DLBCL. Targeting p63 expression and 
function may be a novel therapeutic strategy for 
particular subgroups of DLBCL patients.   
 
MATERIALS AND METHODS   
 
Patients. A total of 795 patients with de novo DLBCL 
from 20 medical centers treated with R-CHOP were 
studied, randomly divided into a training set (n=520) 
and a validation set (n=275). The diagnostic criteria, 
selection process, therapy, and treatment response have 
been described previously [37]. The study was approved 
as being of minimal or no risk or as exempt by the 
  
www.impactaging.com                    361                                     AGING, February  2016, Vol. 8 No.2
institution review boards of all participating medical 
centers.  
 
Immunohistochemistry. Tissue microarrays prepared 
from the diagnostic formalin-fixed, paraffin-embedded 
(FFPE) tissue blocks of all patients studied were stained 
with an anti-p63 antibody (4A4, Santa Cruz 
Biotechnology, Santa Cruz, CA) which can detect all 
p63 isoforms. Expression levels of p63 were determined 
by estimating the percentage of p63-positive tumor cells 
in the tissue array cores. X-tile software and receiver 
operating characteristic curve analysis by GraphPad 
Prism 6 Software were used to determine the percentage 
of p63-positive cells with maximal discriminatory 
power for the separation of DLBCL patients into 2 
different prognostic groups. Evaluation of other 
biomarkers by immunohistochemistry was also 
performed on tissue microarrays using corresponding 
antibodies: p53 (DO-7, Dako, Carpinteria, CA), MDM2 
(IF2, Calbiochem, Billerica, MA), p21 (Dako), Bcl-2 
(Clone-124, Dako, Carpinteria, CA), Ki-67 (Dako), 
CD30 (clone BerH2, Dako), Bcl-6 (Dako), FOXP1 
(Abcam), IRF4/MUM1 (Dako),  CD10 (56C6, Vantana), 
c-Rel (Dako), and CXCR4 (Abcam, San Francisco, CA). 
Details of immunohistochemistry procedures and scoring 
processes have been described previously [38, 44, 55-58].  
 
TP53 and TP63 sequencing, fluorescence in situ 
hybridization. Genomic DNA samples were extracted 
from FFPE tissues, and the TP53 coding region and 
splice site sequence were determined for 460 patients in 
the training set using a p53 AmpliChip (Roche Molecular 
Systems, Pleasanton, CA) as described previously [37]. 
TP63 coding region sequence was analyzed by Sanger 
sequencing method. MYC, BCL2, BCL6, and REL gene 
arrangements and copy number aberrations were detected 
by fluorescence in situ hybridization [56, 59, 60]. 
 
Gene expression profiling. Gene expression profiling 
was performed on Affymetrix GeneChips HG-U133 
Plus Version 2.0 (Affymetrix, Santa Clara, CA) using 
total RNAs as described previously [37, 55]. The CEL 
files are deposited in the National Center for 
Biotechnology Information Gene Expression Omnibus 
repository (GSE#31312). The microarray data were 
quantified and normalized by the frozen robust 
multiarray analysis (RMA) algorithm. The differentially 
expressed genes were identified by using multiple t-
tests. 
 
Statistical analysis. The clinical and pathologic features 
at the time of presentation were compared between 
various DLBCL subgroups by using the chi-square test 
and unpaired t test. Correlation between expression of 
different genes or proteins was evaluated by Spearman 
rank correlation. Overall survival (OS) was calculated 
from the date of diagnosis to the date of last follow-up 
or death. Progression-free survival (PFS) was calculated 
from the date of diagnosis to the date of disease 
progression or death. OS and PFS curves of the various 
groups were analyzed by GraphPad Prism 6 software 
using the Kaplan-Meier method, and differences were 
compared with use of the log-rank (Cox-Mantel) test. 
Multivariate analysis was conducted by using the Cox 
proportional hazards regression model with the SPSS 
software version 19.0 (IBM, Armonk, NY). Any 
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